- •Preface to the Second Edition
- •Contents
- •List of Abbreviations
- •1: Epidemiology of AMD
- •Core Messages
- •1.1 Introduction
- •1.3 Frequency
- •1.3.1 Prevalence
- •1.3.2 Incidence
- •1.4 Natural Course
- •1.5 Genetic Factors
- •1.5.1 The Complement Pathway Genes
- •1.5.1.1 Complement Factor H (CFH)
- •1.5.1.3 Complement Component 3 (C3)
- •1.5.1.4 Complement Factor I (CFI)
- •1.5.2 The ARMS2 (10q26) Locus
- •1.5.3.1 Apolipoprotein E (APOE)
- •1.5.4 Candidate Gene Association Studies
- •1.6 Environmental Factors
- •1.6.1 Smoking
- •1.6.2 Antioxidants
- •1.6.3 Body Mass Index (BMI)
- •1.6.4 Hypertension
- •1.6.5 Cataract Surgery
- •1.7 Interaction Between Risk Determinants
- •1.7.1 Combined Effects of CFH Y402H and Other Genetic and/or Environmental Factors
- •1.7.2 Combined Effects of 10q26 SNPs and Other Genetic and/or Environmental Factors
- •1.7.4 Combined Effects of the APOE Gene and Other Genetic and/or Environmental Factors
- •References
- •2: Genetics
- •Core Messages
- •2.1 Introduction
- •2.2 Identifying Risk Factors of a Common Disease
- •2.3 Early Findings
- •2.4.1 Functional Implications
- •2.5.1 Functional Implications
- •2.7 Prospects of Genetics in AMD Therapy and Prevention
- •Summary for the Clinician
- •References
- •Core Messages
- •3.1 Introduction
- •3.2 Cause and Consequences of Ageing
- •3.3 Clinical Changes Associated with Retinal Ageing
- •3.4 Ageing of the Neural Retina
- •3.5 Ageing of the RPE
- •3.5.1 Changes in RPE Cell Density
- •3.5.2 Subcellular Changes in the RPE
- •3.5.3 Accumulation of Lipofuscin
- •3.5.4 Melanosomes and Pigment Complexes
- •3.5.7 Antioxidant Capacity of the RPE
- •3.6 Ageing of Bruch’s Membrane
- •3.7 The Association Between Ageing and AMD
- •Summary for the Clinician
- •References
- •Core Messages
- •4.1 Introduction
- •4.2 The Complement System
- •4.3 Evidence for Involvement of the Complement System in AMD Pathogenesis
- •4.4.2 Complement Gene Variants and AMD Subtypes
- •4.4.3 Complement Gene Variants and Progression of AMD
- •4.4.5 Variations of Complement Genes and Response to Treatment: Pharmacogenetics
- •4.5 Emerging Pharmacological Intervention Targeting Complement Dysregulation
- •Conclusions
- •Summary for the Clinician
- •References
- •5: Histopathology
- •Core Messages
- •5.1 Retinal Pigment Epithelium
- •5.1.1 Structure and Function of the Retinal Pigment Epithelium
- •5.1.3 Deposits in the RPE
- •5.2 Bruch’s Membrane
- •5.2.1 Structure of Bruch’s Membrane
- •5.2.3 Deposits in Bruch’s Membrane, Drusen
- •5.3 Choroidal Neovascularization
- •5.4 Detachment of the Retinal Pigment Epithelium
- •5.5 Geographic Atrophy of the RPE
- •Summary for the Clinician
- •References
- •6: Early AMD
- •Core Messages
- •6.1 Introduction
- •6.2 Drusen
- •6.2.3 Fluorescence Angiography and Optical Coherence Tomography
- •6.3 Focal Hypopigmentation and Hyperpigmentation of the Retinal Pigment Epithelium
- •6.4 Abnormal Choroidal Perfusion
- •Summary for the Clinician
- •References
- •Core Messages
- •7.1 Introduction
- •7.2.1 Decreased Visual Acuity
- •7.2.2 Visual Distortion
- •7.2.3 Visual Field Defects
- •7.2.4 Miscellaneous Symptoms
- •7.3 Signs of Choroidal Neovascularization
- •7.3.1 Hemorrhage
- •7.3.2 Macular Edema and Subretinal Fluid
- •7.3.3 Retinal Pigment Epithelial Detachment
- •7.3.4 Miscellaneous Signs
- •7.4 Common Testing Modalities to Diagnose Choroidal Neovascularization
- •7.4.1 Fluorescein Angiography
- •7.4.2 Indocyanine Green Angiography
- •7.4.4 Optical Coherence Tomography
- •Summary for the Clinician
- •References
- •8: Geographic Atrophy
- •Core Messages
- •8.1 Introduction
- •8.3 Histology and Pathogenesis of Geographic Atrophy
- •8.5 Spectral Domain Optical Coherence Tomography in Geographic Atrophy
- •8.7 Risk Factors
- •8.7.1 Genetic Factors
- •8.7.2 Systemic Risk Factors
- •8.7.3 Ocular Risk Factors
- •8.8 Development of CNV in Eyes with GA
- •8.9 Visual Function in GA Patients
- •8.9.1 Measurement of Visual Acuity
- •8.9.2 Contrast Sensitivity
- •8.9.3 Reading Speed
- •8.9.4 Fundus Perimetry
- •8.10 Perspectives for Therapeutic Interventions
- •8.10.2 Complement Inhibition
- •8.10.3 Neuroprotection
- •8.10.4 Alleviation of Oxidative Stress
- •8.10.5 Serotonin-1A-Agonist
- •8.10.6 Perspective
- •Summary for the Clinician
- •References
- •9: Fundus Imaging of AMD
- •Core Messages
- •9.1 Introduction
- •9.2 Color Photography
- •9.3 Monochromatic Photography
- •9.5 Optical Coherence Tomography
- •9.5.2 Coherence Length
- •9.5.3 Time Domain Optical Coherence Tomography
- •9.5.4 Frequency Domain Optical Coherence Tomography
- •9.5.5 Increasing Depth of Imaging
- •9.5.6 General Optical Coherence Tomographic Imaging Characteristics of the Macular Region
- •9.6 Fundus Angiography
- •9.6.1 Fluorescein Dye Characteristics
- •9.6.2 Indocyanine Green Dye Characteristics
- •9.6.3 Cameras Used in Fluorescence Angiography
- •9.6.4 Patient Consent and Instruction
- •9.6.5 Fluorescein Injection
- •9.6.6 Fluorescein Technique
- •9.6.7 Indocyanine Green Technique
- •9.7 Fluorescein Angiographic Interpretation
- •9.7.1 Filling Sequence
- •9.7.2 The Macula
- •9.8 Deviations from Normal Angiographic Appearance
- •9.10.1 Drusen
- •9.12 Neovascular AMD
- •9.13 Retinal Pigment Epithelial Detachments
- •9.14 Retinal Vascular Contribution to the Exudative Process
- •9.15 Follow-up
- •9.15.1 Thermal Laser
- •9.15.2 Photodynamic Therapy
- •9.15.3 Anti-VEGF Therapy
- •Summary for the Clinician
- •References
- •10: Optical Coherence Tomography
- •10.1 Introduction
- •Core Messages
- •10.4 OCT in Geographic Atrophy
- •10.5 OCT in Exudative AMD
- •Summary for Clinician
- •References
- •11: Microperimetry
- •Core Messages
- •11.1 Introduction
- •11.2.1 From Manual to Automatic Microperimetry
- •11.2.2 Automatic Microperimetry
- •11.2.3 Microperimetry: The Examination
- •11.2.4 Microperimetry: Test Evaluation
- •11.2.5 Other Microperimeter
- •11.3 Microperimetry in AMD
- •11.3.1 Early AMD
- •11.3.2 Geographic Atrophy
- •11.3.3 Neovascular AMD
- •11.3.4 Neovascular AMD: Treatment
- •Summary for the Clinician
- •References
- •Core Messages
- •12.1 Introduction
- •12.2 Antioxidants and Zinc
- •12.3 Beta-Carotene
- •12.4 Macular Xanthophylls
- •12.6 Vitamin E
- •12.7 Vitamin C
- •12.8 Zinc
- •12.10 AREDS2
- •Summary for the Clinician
- •References
- •Core Messages
- •13.1 Introduction
- •13.2 Basic Principles
- •13.2.1 Clinical Background
- •13.2.2 Laser Photocoagulation
- •13.2.3 Photodynamic Therapy
- •13.3 Treatment Procedures
- •13.3.1 Laser Photocoagulation
- •13.3.2 Photodynamic Therapy
- •13.4 Study Results
- •13.4.1 Laser Photocoagulation
- •13.4.1.1 Extrafoveal CNV
- •13.4.1.2 Subfoveal CNV
- •13.4.1.3 Meta-analysis
- •13.4.2 Photodynamic Therapy
- •13.4.2.1 Predominantly Classic
- •13.4.2.2 Occult with No Classic Neovascularization
- •13.4.2.3 Minimally Classic
- •13.5 Safety and Adverse Events
- •13.5.1 Laser Photocoagulation
- •13.5.2 Photodynamic Therapy
- •13.6 Variations
- •13.6.1 Laser Photocoagulation: Different Wavelengths
- •13.6.2 Photodynamic Therapy
- •13.6.3 Combination Treatments
- •13.7 Present Guidelines
- •13.7.1 Laser Photocoagulation
- •13.7.2 Photodynamic Therapy
- •13.8 Perspectives
- •Summary for the Clinician
- •References
- •Core Messages
- •14.1 Introduction
- •14.2 Vascular Endothelial Growth Factor (VEGF)
- •14.3 Targets Within the VEGF Pathway
- •14.3.1 Sequestration of Released VEGF
- •14.3.2 Inhibition of VEGF and VEGF Receptor Synthesis by Small Interfering RNA (siRNA)
- •14.3.3 Inhibition of the Intracellular Signal Cascade
- •14.3.4 Natural VEGF Inhibitors
- •14.4 New Methods of Drug Delivery
- •14.5 Combined Strategies
- •Summary for the Clinician
- •References
- •Core Messages
- •15.1 Introduction
- •15.1.1 Anti-VEGF Therapies for NV-AMD
- •15.2.1 How Should Neovascular AMD be Diagnosed?
- •15.2.4.1 Results with Continuous Monthly Treatment
- •15.2.4.2 How Should Treatment be Started?
- •15.2.4.3 What Flexible Approaches Are Reported?
- •Fixed Quarterly Injection Studies
- •Flexible Dosing Regimens: Two Approaches
- •Flexible Dosing Regimens: ‘As Needed’ Approach
- •Flexible Dosing Regimens: ‘Treat-and-Extend’ Approach
- •Summary for the Clinician
- •References
- •Core Messages
- •16.1 Introduction
- •16.3 Current Limitation of Therapy in the Treatment of Exudative AMD
- •16.4 Rationale for Combination Therapy in the Treatment of Exudative AMD
- •16.5 Clinical Data Examining Combination Therapy for Exudative AMD
- •16.5.3 Triple Therapy for Exudative AMD
- •16.5.4 Combination Therapy with Radiation
- •Summary for the Clinician
- •References
- •Core Messages
- •17.1 Introduction
- •17.2 Current Treatment Options for Dry AMD
- •17.3 Targeting the Cause of AMD
- •17.4 Preclinical and Phase I Drugs in Development for Dry AMD
- •17.4.1 Clinical Trial Endpoints in Dry AMD
- •Trimetazidine
- •17.4.2.2 Neuroprotection
- •Ciliary Neurotrophic Factor (CNTF/NT-501)
- •AL-8309B (Tandospirone)
- •Brimonidine Tartrate Intravitreal Implant
- •17.4.2.3 Visual Cycle Modulators
- •Fenretinide
- •17.4.2.4 Other
- •17.4.3 Drugs to Prevent Injury from Oxidative Stress and Micronutrient Depletion
- •17.4.4.1 Complement Inhibition at C3
- •17.4.4.2 Complement Inhibition at C5
- •Eculizumab
- •17.4.4.3 Complement Inhibition of Factor D
- •FCFD4514S
- •Iluvien
- •Glatiramer Acetate (Copaxone)
- •17.5 Summary
- •Summary for the Clinician
- •References
- •18: Surgical Therapy
- •Core Messages
- •18.1 Maculoplasty
- •18.2 Macular Translocation
- •18.3 Single Cell Suspensions
- •18.5 Indications for Surgery
- •18.5.1 Non-responder
- •18.5.2 Pigment Epithelium Rupture
- •18.5.3 Massive Submacular Bleeding
- •18.5.5 Macula Dystrophies
- •Summary for the Clinician
- •References
- •19: Reading with AMD
- •Core Messages
- •19.1 Introduction
- •19.2 Physiological Principles
- •19.3 Reading with a Central Scotoma
- •19.3.1.2 The Reading Visual Field Related to the Fundus (Fig. 19.4b)
- •19.3.1.3 The Reading Visual Field Related to the Text (Fig. 19.4c)
- •19.3.1.4 Eccentric Fixation Related to the Globe (Fig. 19.5)
- •19.3.3 Examination of Fixation Behaviour
- •19.3.4 Motor Aspects
- •19.4 Methods to Examine Reading Ability
- •19.5 Rehabilitation Approaches to Improve Reading Ability
- •Summary for the Clinician
- •References
- •20: Low Vision Aids in AMD
- •Core Messages
- •20.2 Effects of Visual Impairment in AMD
- •20.5 Optical Magnifying Visual Aids for Distance
- •20.5.1 Aids for Watching Television
- •20.8 Electronic Reading Instruments
- •20.9 Additional Aids
- •20.10 Noteworthy Details for the Provision of Low Vision Aids
- •20.11 Basic Information on Prescription
- •Summary for the Clinician
- •References
- •Index
Fundus Imaging of AMD |
9 |
|
|
R.F. Spaide |
|
Core Messages |
9.1 |
Introduction |
|
|
|
|
|
|
›There are various methods of imaging the fundus. Each method has strengths and weaknesses in what it can show. There is no one method that is best to image all we need to know about the fundus.
›Photographic records of the fundus are very helpful during follow-up examinations and also serve as a resource for research. Component channels of the color photograph can be individually inspected.
›Autofluorescence imaging reveals not only the topographic structure of the retinal pigment epithelial monolayer, but also supplies information such that inferences about the health of the RPE can be made.
›Optical coherence tomography is a valuable tool that gives anatomic cross-sectional information about the retina, retinal pigment epithelium, and choroid.
›Fluorescein and indocyanine green angiography are the standards for diagnosing choroidal neovascularization.
R.F. Spaide
Vitreous-Retina-Macula Consultants of New York, Manhattan Eye, Ear, and Throat Hospital,
New York, NY, USA
e-mail: rickspaide@yahoo.com
The advancement of the study of retinal diseases has been highly dependent on the expanding ability to image the ocular fundus. Monochromatic and color photography provided a means to photographically record the fundus. The advent of fluorescein angiography afforded ophthalmologists with a way to investigate and document vascular anatomy and physiology in ways previously unattainable [1]. Indocyanine green angiography augmented our capability to image the ocular circulation, particularly in the choroid [2]. With these dyes, we could obtain indirect information about other layers of the fundus, particularly the retinal pigment epithelium (RPE). These indirect methods included looking for increased or decreased transmission of underlying choroidal fluorescence, assessing the amount of staining and leakage, and using stereoscopic clues to try to determine the contour at the level of the RPE. Autofluorescence imaging [3], using several interrelated physiologic principles, provided the ability for clinicians to evaluate the RPE and outer retina in both an anatomic and functional basis. Optical coherence tomography (OCT) vastly improved our resolving power in imaging the anatomy of the retina and the RPE, but in its earlier iterations did not offer much in terms of functional imaging. Later implementation of OCT allowed visualization of the choroid in a number of diseases, particularly age-related macular degeneration (AMD). Each of these imaging methods will be discussed in isolation, much the same way tennis instruction is divided into forehand, backhand, volley, and the like, but in practical use, they are all employed simultaneously.
F.G. Holz et al. (eds.), Age-related Macular Degeneration, |
141 |
DOI 10.1007/978-3-642-22107-1_9, © Springer-Verlag Berlin Heidelberg 2013 |
|
142 |
R.F. Spaide |
|
|
9.2Color Photography
Fundus cameras originally had 35-mm camera backs that were loaded with film. Images were recorded on film, the film was developed, and then had to be placed in the appropriate patient’s records. With the improving capabilities of charged coupled devices (CCDs), the increased speed of personal computers, and the tremendous decrease in cost of information storage, digital photography became not only cheaper, but better than film-based imaging for many modalities. Color image quality is judged by several factors including color accuracy, resolution, noise, dynamic range, and sensitivity. The spatial resolution of film is similar to that of high-quality scientific CCDs, but the other parameters are generally better with CCDs as compared with film. An equally if not more important aspect of digital imaging is that if an image has poor quality, it can instantly be retaken. High-resolution color photography is a practical way to record baseline and follow-up images of patients with AMD. Color photographs inherently are composed of red, green, and blue images, which can be deconstructed for analysis. The green channel of the color photograph is essentially equivalent to a conventional monochromatic image.
9.3Monochromatic Photography
When film was used to record fundus images, it was common to take a picture of the eye with a green filter in place of the light path. For some peculiar reason, this green filter monochromatic light was called “red-free” photography. Green light has the advantage of making small hemorrhages appear dark. When digital imaging started, color CCD cameras were expensive and had poor resolution. Monochromatic CCDs had a higher resolution for any given cost, and therefore, monochromatic photographs continued to be used. With the advent of high-resolution color CCDs, there is little reason to get a “red-free” photograph, especially since the green channel of a color photograph can be inspected. Other wavelengths of light may be more useful. A particular type of drusen, first called reticular pseudodrusen, are much easier to see with either infrared or blue light as compared with red or green monochromatic photography. One way to take a photograph with blue light (actually blue-green light) is to use the excitation filter for fluorescein angiography without using the barrier filter. This is a common technique to evaluate patients for the presence of reticular pseudodrusen, now termed
subretinal drusenoid deposits. It is easy to separate the principal color components of a color photograph into the red, green, and blue channels, and this latter way has become another common way to look for subretinal drusenoid deposits (Fig. 9.1).
The commercial scanning laser ophthalmoscopes (SLOs), as manufactured by Heidelberg Engineering, use near-infrared light to image the fundus. The reflectance characteristics of fundus structures are much different with near-infrared light as compared with visible light. The optic nerve is not particularly reflective in near-infrared light and consequently appears dark. Melanin absorbs visible light, particularly blue light; near-infrared light is not absorbed as much by melanin. In addition, melanin is a good reflector of infrared light, and consequently, pigmented scars can appear bright. Subretinal drusenoid deposits are readily visible with SLO examination (Fig. 9.2).
9.4Autofluorescence Imaging
Autofluorescent imaging of the ocular fundus relies on the stimulated emission of light from molecules, chiefly lipofuscin, in the retinal pigment epithelium [4–6]. Lipofuscin is a diverse group of molecular species [6], yellow to brown in color that accumulates in all post-mitotic cells, from the oxidative breakdown and rearrangement of a number of different molecules including polyunsaturated fatty acids and proteins. Lipofuscin in the RPE is novel because of the source of the components of lipofuscin, which is the outer segments of the photoreceptors.
The main component of lipofuscin in RPE cells is A2E, which is formed from two molecules of transretinal and one molecule of phosphatidylethanolamine. Components of lipofuscin inhibit lysosomal protein degradation [7], are photoreactive [8], are capable of producing a variety of reactive oxygen species and other radicals [5], are amphiphilic, may induce apoptosis of the RPE [9], and mediate blue light–induced RPE apoptosis [10]. Precursors of A2E, such as A2PE-H2, A2PE, and A2-rhodopsin, all of which are autofluorescent, form in outer segments prior to phagocytosis by the RPE [11, 12]. Because of the lack of direct apposition of the photoreceptor outer segments with the RPE and the inherent delay in phagocytosis, greater yields of A2-PE by the reaction product between all- trans-retinal and phosphatidylethanolamine are possible. In addition, the A2E and its precursors are potentially susceptible to oxidative damage [13, 14]
9 Fundus Imaging of AMD |
143 |
|
|
Fig. 9.1 Modern digital color imaging provides high-resolution images of the fundus and the color photograph shown can be split into the three constituent color channels: red, green, and blue.
Note the drusen present in this eye are more easily seen in the blue channel, consistent with the presence of reticular pseudodrusen, which were renamed subretinal drusenoid deposits
Fig. 9.2 Top left, subretinal drusenoid deposits. Top right, near-infrared; and lower left, autofluorescence images. Lower right, OCT showing subretinal deposits
